 The FDA has granted Fast Track designation to Alkermes plcs NASDAQ: ALKS nemvaleukin alfa nemvaleukin for mucosal melanoma. Nemvaleukin is an investigational engineered interleukin-2 IL-2 variant immunotherapy. 